Mayo Clinic at the American Society
of Clinical Oncology (ASCO)

Mayo Clinic is contributing 60 educational sessions, posters and abstracts at the 2009 annual meeting of the American Society of Clinical Oncology. Below are some featured research projects.

Featured Mayo Clinic Research

Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.
Researcher Keith Bible, M.D., Ph.D., discusses the research on the Mayo Clinic News Blog.

Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).
Mayo Clinic's Ivana Micallef, M.D., discusses the research on the Mayo Clinic News Blog.

Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Researcher Charles Loprinzi, M.D. discusses this research in a video on the Mayo Clinic News Blog.

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

Chemotherapy Combination Outcomes Differ for Aged, Younger Colon Cancer Patients
The combination of chemotherapies 5FU and oxaliplatin, compared to 5FU alone, decreases colon cancer recurrence after surgery and promotes longer survival for patients under 70 — but not for those who are older.